Investment
Features
FeesSafety
Academy
More
Pluang+

Compare KraneShares CSI China Internet ETF (KWEB) vs GeneDx Holdings Corp (WGS) Price & Performance

KraneShares CSI China Internet ETFTrade
GeneDx Holdings CorpTrade

Price performance (Past 24H)

Key statistics

KraneShares CSI China Internet ETF vs GeneDx Holdings Corp — how do they compare? KraneShares CSI China Internet ETF trades at $27.75, while GeneDx Holdings Corp trades at $81.98 (market cap $2.32B). The key difference: GeneDx Holdings Corp is trading nearer its 52-week high, KraneShares CSI China Internet ETF nearer its low. Which is the better fit depends on your goals.

KWEBWGS
Sector
Sector/ThematicTechnology
52-Week High
$42.94$167.51
52-Week Low
$23.63$34.51
Market Cap
$2.32B
Enterprise Value
$2.35B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

KraneShares CSI China Internet ETF

KWEB, the KraneShares CSI China Internet ETF, trades at $28.66, up 0.99% on the day, with a bullish technical signal from moving averages and strong trend strength indicated by ADX. Recent news highlights institutional buying, China's export growth, and AI-driven factory rebounds, though RSI levels suggest potential overbought conditions. The ETF provides exposure to Chinese internet and AI companies, with performance influenced by economic policies and tech sector developments.

The outlook for KWEB is cautiously optimistic, driven by AI expansion and government support, but risks include U.S.-China tensions and regulatory shifts. Investors may find value in its tech concentration, yet must weigh geopolitical and market volatility. Analyst sentiment is mixed, balancing growth potential against structural risks.

GeneDx Holdings Corp

GeneDx Holdings Corp. (WGS) trades at $77.08, up 10.76% today, showing strong momentum despite negative profitability metrics. The stock exhibits bullish technical signals with support at $72 and resistance at $80. Recent Q2 2026 earnings beat expectations with $0.01 EPS versus -$0.19 estimate, while revenue reached $114.4 million. However, the company faces significant challenges with a -23.4% net income margin and ongoing securities class action litigation.

Investment outlook remains cautiously optimistic given strong analyst support (90.9% buy rating) and $79.25 consensus price target. Key opportunities include growing genomic testing volumes and improved operational efficiency, while risks center on profitability challenges, legal liabilities, and high valuation multiples that may not justify current fundamentals.

Returns comparison

Trailing returns across standard periods

About KraneShares CSI China Internet ETF

KWEB tracks the CSI Overseas China Internet Index, providing exposure to Chinese software and services companies listed in the US and Hong Kong, including giants like Tencent, Alibaba, and Meituan.

Read more on KWEB

About GeneDx Holdings Corp

GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.

Read more on WGS